Company: IMNN
Filing Date: 2025-03-19
Form Type: DRS
Source: 0001641172-25-000007
Chunk: 23

Company: Imunon, Inc.
Filing Date: 2025-03-19
Form: DRS
Chunk 23
---

 shares of Common Stock issuable upon the exercise of outstanding stock options as of December 31, 2024, having a weighted average     
 exercise price of $1.95 per share;                                                                                                    |
| ● | 39,700                                                                                                                                
 shares of Common Stock issuable upon the vesting of Common Stock awards as of December 31, 2024, having a weighted average grant      
 date fair value of $0.99 per share;                                                                                                   |
| ● | 5,155,060                                                                                                                             
 shares of Common Stock issuable upon the exercise of outstanding warrants as of December 31, 2024, having a weighted average exercise 
 price of $2.51 per share; and                                                                                                         |
| ● | 420,000                                                                                                                               
 shares of Common Stock reserved for future issuance pursuant to our existing stock incentive plan.                                    |

To the extent that any outstanding stock options or warrants are exercised, new stock options are issued under our stock incentive plans, or we otherwise issue additional shares of Common Stock or securities convertible into or exercisable for Common Stock in the future, at a price less than the public offering price, there will be further dilution to new investors.

The information discussed above is illustrative only and will adjust based on the actual public offering price and other terms of this offering determined at pricing. Except as indicated otherwise, the discussion and table above assume no exercise of common warrants offered hereby and no sale of pre-funded warrants, which, if sold, would reduce the number of shares of Common Stock that we are offering on a one-for-one basis.

| 11 |

| CONFIDENTIAL TREATMENT REQUESTED BY IMUNON, INC.PURSUANT TO 17 C.F.R. SECTION 200.83 |

<div align='center'>USE OF PROCEEDS</div>

We estimate that we will receive net proceeds from this offering of approximately $[●] million (assuming the sale of the maximum number of securities offered hereby), based upon an assumed public offering price of $[●] per share of Common Stock and accompanying common warrant (which is the last reported sale price of our Common Stock on Nasdaq on [●], 2025), after deducting the estimated Placement Agent fees and estimated offering expenses payable by us and assuming no issuance of any pre-funded warrants and no exercise of the common warrants. However, because this is a reasonable best-efforts offering with no minimum number of securities or amount of proceeds as a condition to closing, the actual offering amount, Placement Agent